BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22893371)

  • 1. Machine learning-based method for personalized and cost-effective detection of Alzheimer's disease.
    Escudero J; Ifeachor E; Zajicek JP; Green C; Shearer J; Pearson S;
    IEEE Trans Biomed Eng; 2013 Jan; 60(1):164-8. PubMed ID: 22893371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local MRI analysis approach in the diagnosis of early and prodromal Alzheimer's disease.
    Chincarini A; Bosco P; Calvini P; Gemme G; Esposito M; Olivieri C; Rei L; Squarcia S; Rodriguez G; Bellotti R; Cerello P; De Mitri I; Retico A; Nobili F;
    Neuroimage; 2011 Sep; 58(2):469-80. PubMed ID: 21718788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How early can we predict Alzheimer's disease using computational anatomy?
    Adaszewski S; Dukart J; Kherif F; Frackowiak R; Draganski B;
    Neurobiol Aging; 2013 Dec; 34(12):2815-26. PubMed ID: 23890839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.
    Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P
    J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel method for early diagnosis of Alzheimer's disease based on pseudo Zernike moment from structural MRI.
    Gorji HT; Haddadnia J
    Neuroscience; 2015 Oct; 305():361-71. PubMed ID: 26265552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inexpensive, non-invasive biomarkers predict Alzheimer transition using machine learning analysis of the Alzheimer's Disease Neuroimaging (ADNI) database.
    Beltrán JF; Wahba BM; Hose N; Shasha D; Kline RP;
    PLoS One; 2020; 15(7):e0235663. PubMed ID: 32716914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
    Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
    Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A disease state fingerprint for evaluation of Alzheimer's disease.
    Mattila J; Koikkalainen J; Virkki A; Simonsen A; van Gils M; Waldemar G; Soininen H; Lötjönen J;
    J Alzheimers Dis; 2011; 27(1):163-76. PubMed ID: 21799247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Robust Deep Model for Improved Classification of AD/MCI Patients.
    Li F; Tran L; Thung KH; Ji S; Shen D; Li J
    IEEE J Biomed Health Inform; 2015 Sep; 19(5):1610-6. PubMed ID: 25955998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved Diagnostic Multimodal Biomarkers for Alzheimer's Disease and Mild Cognitive Impairment.
    Martínez-Torteya A; Treviño V; Tamez-Peña JG
    Biomed Res Int; 2015; 2015():961314. PubMed ID: 26106620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-modality sparse representation-based classification for Alzheimer's disease and mild cognitive impairment.
    Xu L; Wu X; Chen K; Yao L
    Comput Methods Programs Biomed; 2015 Nov; 122(2):182-90. PubMed ID: 26298855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting the conversion of mild cognitive impairment to Alzheimer's disease based on the volumetric measurements of the selected brain structures in magnetic resonance imaging.
    Nesteruk M; Nesteruk T; Styczyńska M; Barczak A; Mandecka M; Walecki J; Barcikowska-Kotowicz M
    Neurol Neurochir Pol; 2015; 49(6):349-53. PubMed ID: 26652867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Random Forest ensembles for detection and prediction of Alzheimer's disease with a good between-cohort robustness.
    Lebedev AV; Westman E; Van Westen GJ; Kramberger MG; Lundervold A; Aarsland D; Soininen H; Kłoszewska I; Mecocci P; Tsolaki M; Vellas B; Lovestone S; Simmons A;
    Neuroimage Clin; 2014; 6():115-25. PubMed ID: 25379423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers in preclinical Alzheimer's disease.
    Chong MS; Lim WS; Sahadevan S
    Curr Opin Investig Drugs; 2006 Jul; 7(7):600-7. PubMed ID: 16869111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining multivariate normative rules for healthy aging using neuroimaging and machine learning: an application to Alzheimer's disease.
    Andrade de Oliveira A; Carthery-Goulart MT; Oliveira Júnior PP; Carrettiero DC; Sato JR
    J Alzheimers Dis; 2015; 43(1):201-12. PubMed ID: 25079801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
    Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
    Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative evaluation of disease progression in a longitudinal mild cognitive impairment cohort.
    Runtti H; Mattila J; van Gils M; Koikkalainen J; Soininen H; Lötjönen J;
    J Alzheimers Dis; 2014; 39(1):49-61. PubMed ID: 24121959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classification and prediction of clinical diagnosis of Alzheimer's disease based on MRI and plasma measures of α-/γ-tocotrienols and γ-tocopherol.
    Mangialasche F; Westman E; Kivipelto M; Muehlboeck JS; Cecchetti R; Baglioni M; Tarducci R; Gobbi G; Floridi P; Soininen H; Kłoszewska I; Tsolaki M; Vellas B; Spenger C; Lovestone S; Wahlund LO; Simmons A; Mecocci P;
    J Intern Med; 2013 Jun; 273(6):602-21. PubMed ID: 23343471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.